/주식/UTHR
UTHR

UTHR

USD

United Therapeutics Corporation Common Stock

$437.330+4.580 (1.058%)

실시간 가격

Healthcare
Drug Manufacturers - Specialty & Generic
미국

가격 차트

Loading Chart...

핵심 지표

시장 지표
기업 기본 정보
거래 통계

시장 지표

시가

$432.750

고가

$440.000

저가

$430.020

거래량

0.35M

기업 기본 정보

시가총액

18.8B

산업

Drug Manufacturers - Specialty & Generic

국가

United States

거래 통계

평균 거래량

0.79M

거래소

NMS

통화

USD

52주 범위

저가 $266.98현재가 $437.330고가 $479.5

관련 뉴스

BusinessWire

United Therapeutics Corporation to Present at Upcoming Investor Conferences

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that company executives will provide an overview and update on the company during fireside chat sessions at two upcoming

더 보기
United Therapeutics Corporation to Present at Upcoming Investor Conferences
BusinessWire

United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease

Ongoing EXPAND Study is the First Clinical Trial to Evaluate Xenotransplantation in End-Stage Renal Disease United Therapeutics Corporation (Nasdaq: UTHR) today announced the first clinical xenotransplantation in its

더 보기
United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on United Therapeutics, Raises Price Target to $525

HC Wainwright & Co. analyst Andrew S. Fein maintains United Therapeutics with a Buy and raises the price target from $500 to $525.

더 보기
HC Wainwright & Co. Maintains Buy on United Therapeutics, Raises Price Target to $525
Analyst Upgrades

RBC Capital Maintains Outperform on United Therapeutics, Raises Price Target to $587

RBC Capital analyst Lisa Walter maintains United Therapeutics with a Outperform and raises the price target from $569 to $587.

더 보기
RBC Capital Maintains Outperform on United Therapeutics, Raises Price Target to $587
Analyst Upgrades

Wells Fargo Maintains Equal-Weight on United Therapeutics, Raises Price Target to $423

Wells Fargo analyst Benjamin Burnett maintains United Therapeutics with a Equal-Weight and raises the price target from $414 to $423.

더 보기
Wells Fargo Maintains Equal-Weight on United Therapeutics, Raises Price Target to $423
BusinessWire

United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced record financial results for the quarter ended September 30, 2025, driven by continued year-over-year revenue growth in key

BusinessWire

United Therapeutics Corporation to Report Third Quarter 2025 Financial Results Before Market Open on Wednesday, October 29, 2025

United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2025 financial results before the market opens on Wednesday, October 29, 2025. A press release detailing the quarterly